Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.
Tingjian YanMallik GreeneEunice ChangChristy R HouleMarian H TarboxMichael S BroderPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
In MDD, brexpiprazole users had significantly lower psychiatric costs than lurasidone and quetiapine users, and significantly lower psychiatric hospitalization risk than quetiapine users. Adjunctive AAP choice may impact subsequent healthcare costs and utilization in MDD.